Abstract
Since the discovery almost fifteen years ago that E2F transcription factors are key targets of the retinoblastoma protein (RB), studies of the E2F family have uncovered critical roles in the control of transcription, cell cycle and apoptosis. E2F proteins are encoded by at least eight genes, E2F1 through E2F8. While specific roles for individual E2Fs in mediating the effects of RB loss are emerging, it is also becoming clear that there are no simple divisions of labor among the E2F family. Instead, an individual E2F can function to activate or repress transcription, promote or impede cell cycle progression and enhance or inhibit cell death, dependent on the cellular context. While functional redundancy among E2Fs and the striking influences of cellular context on the effects of E2F loss or gain of function have prevented a simple delineation of unique functions within the E2F family, these complexities undoubtedly reflect the extensive regulation and importance of this transcription factor family.
Keywords: retinoblastoma protein, DNA damage, E2F deficient cells, transcription, hypophosphorylated RB
Current Molecular Medicine
Title: Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis
Volume: 6 Issue: 7
Author(s): James DeGregori and David G. Johnson
Affiliation:
Keywords: retinoblastoma protein, DNA damage, E2F deficient cells, transcription, hypophosphorylated RB
Abstract: Since the discovery almost fifteen years ago that E2F transcription factors are key targets of the retinoblastoma protein (RB), studies of the E2F family have uncovered critical roles in the control of transcription, cell cycle and apoptosis. E2F proteins are encoded by at least eight genes, E2F1 through E2F8. While specific roles for individual E2Fs in mediating the effects of RB loss are emerging, it is also becoming clear that there are no simple divisions of labor among the E2F family. Instead, an individual E2F can function to activate or repress transcription, promote or impede cell cycle progression and enhance or inhibit cell death, dependent on the cellular context. While functional redundancy among E2Fs and the striking influences of cellular context on the effects of E2F loss or gain of function have prevented a simple delineation of unique functions within the E2F family, these complexities undoubtedly reflect the extensive regulation and importance of this transcription factor family.
Export Options
About this article
Cite this article as:
DeGregori James and Johnson G. David, Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070739
DOI https://dx.doi.org/10.2174/1566524010606070739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry New Thermoresponsive Eyedrop Formulation Containing Ibuprofen Loaded-Nanostructured Lipid Carriers (NLC): Development, Characterization and Biocompatibility Studies
Current Drug Delivery Differential Expression of miR-20a and miR-145 in Colorectal Tumors as Potential Location-specific miRNAs
MicroRNA Targeting Phospholipase D-mediated Survival Signals in Cancer
Current Signal Transduction Therapy Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Perinatal Management of Fetal Tumors
Current Pediatric Reviews Myc - What We have Learned from Flies
Current Drug Targets Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry